Vaishali Sanchorawala

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5414261/publications.pdf

Version: 2024-02-01

253 papers	9,725 citations	50170 46 h-index	42291 92 g-index
256 all docs	256 docs citations	256 times ranked	4451 citing authors

#	Article	IF	Citations
1	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17.	1.4	22
2	Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrology Dialysis Transplantation, 2022, 37, 1281-1288.	0.4	7
3	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	3.3	29
4	Predictive factors of outcomes in patients with <scp>AL</scp> amyloidosis treated with daratumumab. American Journal of Hematology, 2022, 97, 79-89.	2.0	10
5	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7.	1.4	42
6	Beyond Survival in AL amyloidosis: Identifying and Satisfying Patientsâ€™ Needs. Hemato, 2022, 3, 38-46.	0.2	0
7	Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis. HemaSphere, 2022, 6, e681.	1.2	10
8	Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation. American Journal of Medicine, 2022, 135, S30-S37.	0.6	2
9	Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. Kidney Medicine, 2022, 4, 100427.	1.0	4
10	Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 184-189.	1.4	8
11	Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	1
12	Healthâ€related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasoneâ€‰Â±â€‰daratumumab: Results from the <scp>ANDROMEDA</scp> study. American Journal of Hematology, 2022, 97, 719-730.	2.0	3
13	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. JACC: Cardiovascular Imaging, 2022, 15, 594-603.	2.3	6
14	Prevalence of plasma cell and lymphoproliferative disorders among blood relatives of patients with light chain amyloidosis. British Journal of Haematology, 2022, , .	1.2	0
15	Daratumumab in AL amyloidosis. Blood, 2022, 140, 2317-2322.	0.6	8
16	A novel substitution of proline (P32L) destabilises Î²2-microglobulin inducing hereditary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, , 1-8.	1.4	2
17	Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25â€year longitudinal study. American Journal of Hematology, 2022, 97, 1189-1199.	2.0	12
18	Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.. Journal of Clinical Oncology, 2022, 40, TPS8076-TPS8076.	0.8	6

#	Article	IF	Citations
19	Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer Journal, 2022, 12, .	2.8	0
20	Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia, 2021, 35, 916-919.	3.3	18
21	A pharmacistâ€™s review of the treatment of systemic light chain amyloidosis. Journal of Oncology Pharmacy Practice, 2021, 27, 187-198.	0.5	4
22	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 1-2.	1.4	49
23	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.. Journal of Clinical Oncology, 2021, 39, 8003-8003.	0.8	15
24	Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e460-e463.	0.2	2
25	Detection of minimal residual disease by next generation sequencing in AL amyloidosis. Blood Cancer Journal, 2021, 11, 117.	2.8	6
26	Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 425-426.	0.2	4
27	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	13.9	268
28	Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal, 2021, 11, 139.	2.8	45
29	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10.	2.8	53
30	Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab. Blood, 2021, 138, 2734-2734.	0.6	0
31	Early serum free light chain response after high-dose melphalan and stem cell transplantation predicts hematologic response in AL amyloidosis. Bone Marrow Transplantation, 2021, , .	1.3	0
32	The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 17-24.	1.4	8
33	Establishment of brain natriuretic peptide â€•based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. British Journal of Haematology, 2020, 188, 424-427.	1.2	25
34	Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. American Journal of Hematology, 2020, 95, E45-E48.	2.0	7
35	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1998-2009.	3.3	14
36	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet Journal of Rare Diseases, 2020, 15, 268.	1.2	9

#	Article	IF	Citations
37	Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer Journal, 2020, 10, 118.	2.8	21
38	Systemic Amyloidosis Caused by Monoclonal Immunoglobulins. Hematology/Oncology Clinics of North America, 2020, 34, 1099-1113.	0.9	7
39	Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer Journal, 2020, 10, 88.	2.8	14
40	Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood, 2020, 135, 1541-1547.	0.6	111
41	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	1.2	17
42	Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 244-249.	1.4	27
43	Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. European Journal of Haematology, 2020, 105, 495-501.	1.1	26
44	AL Amyloidosis in Myeloma: Red Flag Symptoms. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 777-778.	0.2	6
45	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology, 2020, 38, 1455-1462.	0.8	31
46	The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney International Reports, 2020, 5, 485-493.	0.4	11
47	High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Acta Haematologica, 2020, 143, 381-387.	0.7	19
48	Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Advances, 2020, 4, 880-884.	2.5	40
49	Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following StemÂCell Transplantation. JACC: CardioOncology, 2020, 2, 721-731.	1.7	11
50	Improved Quantification of CardiacÂAmyloid Burden in SystemicÂLight ChainÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 1325-1336.	2.3	41
51	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. Blood, 2020, 136, 48-50.	0.6	11
52	Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. Blood, 2020, 136, 37-40.	0.6	5
53	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	0.6	146
54	Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546.	0.8	7

#	Article	IF	Citations
55	Successful transition from bortezomib subcutaneous to generic intravenous bortezomib: Cost savings initiative with global economic impact.. Journal of Clinical Oncology, 2020, 38, e19375-e19375.	0.8	0
56	Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes. Blood, 2020, 136, 51-51.	0.6	0
57	Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments. Blood, 2020, 136, 38-39.	0.6	0
58	Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications. Blood, 2020, 136, 23-24.	0.6	0
59	Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Blood, 2020, 136, 4-5.	0.6	0
60	Prevalence and prognostic value of Dâ€dimer elevation in patients with AL amyloidosis. American Journal of Hematology, 2019, 94, 1098-1103.	2.0	12
61	A new era of amyloidosis: the trends at a major US referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 192-196.	1.4	14
62	Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 113-114.	1.4	2
63	Safety of autologous stem cell transplantation in patients with known Human Tâ€cell Lymphotropic Viruses Type 1 and 2 infection: A case series of four patients. American Journal of Hematology, 2019, 94, E317-E319.	2.0	1
64	Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives . Journal of Blood Medicine, 2019, Volume 10, 373-380.	0.7	8
65	High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplantation, 2019, 54, 1304-1309.	1.3	4
66	Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. American Journal of Transplantation, 2019, 19, 3185-3190.	2.6	15
67	Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis. American Journal of Hematology, 2019, 94, E194-E196.	2.0	5
68	Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body ¹⁸F-Florbetapir PET/CT. Journal of Nuclear Medicine, 2019, 60, 1234-1239.	2.8	54
69	Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Advances, 2019, 3, 216-218.	2.5	25
70	Bortezomib ocular toxicities: Outcomes with ketotifen. American Journal of Hematology, 2019, 94, E80-E82.	2.0	11
71	Long-term outcome of kidney transplantation in AL amyloidosis. Kidney International, 2019, 95, 405-411.	2.6	57
72	Cardiac biomarkers and healthâ€related quality of life in patients with light chain (<scp>AL</scp>) amyloidosis. British Journal of Haematology, 2019, 185, 998-1001.	1.2	4

#	Article	IF	Citations
73	Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, e169-e173.	2.0	14
74	Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood, 2019, 133, 215-223.	0.6	118
75	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	0.6	34
76	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	0.6	27
77	Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact. Blood, 2019, 134, 4758-4758.	0.6	3
78	Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study. Blood, 2019, 134, 4578-4578.	0.6	1
79	The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study. Blood, 2019, 134, 4353-4353.	0.6	2
80	Once AL amyloidosis: not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 139-140.	1.4	10
81	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 62-67.	1.4	108
82	Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2018, 93, E129-E132.	2.0	6
83	Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2018, 53, 371-373.	1.3	4
84	Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 1-7.	1.4	18
85	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	18.1	350
86	Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients. Transfusion and Apheresis Science, 2018, 57, 411-415.	0.5	1
87	Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 1823-1827.	2.0	12
88	A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 148-155.	1.4	13
89	Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 156-159.	1.4	12
90	Echocardiography and Survival in Light Chain Cardiac Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007826.	1.3	5

#	Article	IF	Citations
91	Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. Blood, 2018, 132, 755-757.	0.6	4
92	High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. Bone Marrow Transplantation, 2018, 53, 1593-1595.	1.3	2
93	High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 127-132.	2.0	31
94	Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study. Blood, 2018, 132, 2005-2005.	0.6	8
95	Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis. Blood, 2018, 132, 4616-4616.	0.6	0
96	The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades. Blood, 2018, 132, 5536-5536.	0.6	0
97	A Woman in Her 40s With Headache and New-Onset Seizures. JAMA Neurology, 2017, 74, 476.	4.5	0
98	Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 37-41.	1.4	15
99	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605.	0.6	108
100	The six-minute walk test in patients with AL amyloidosis: a single centre case series. British Journal of Haematology, 2017, 177, 388-394.	1.2	12
101	Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1057-1064.	0.5	60
102	A longitudinal evaluation of healthâ€related quality of life in patients with <scp>AL</scp> amyloidosis: associations with health outcomes over time. British Journal of Haematology, 2017, 179, 461-470.	1.2	27
103	Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood, 2017, 130, 1383-1386.	0.6	30
104	The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplantation, 2017, 52, 1349-1351.	1.3	13
105	Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Related Outcome Measures, 2017, Volume 8, 157-167.	0.7	16
106	Penile ulcers complicating systemic AL amyloidosis: a case report. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 203-204.	1.4	3
107	Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Bone Marrow Transplantation, 2016, 51, 1318-1322.	1.3	6
108	David C Seldin, MD, PhD: scientist, clinician, teacher, gentleman, 1957â€“2015. Bone Marrow Transplantation, 2016, 51, 323-323.	1.3	0

#	Article	IF	Citations
109	Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica, 2016, 101, 86-90.	1.7	19
110	Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood, 2016, 128, 1059-1062.	0.6	117
111	Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2016, 91, E458-60.	2.0	16
112	Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 188-193.	1.4	18
113	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 214-220.	1.4	8
114	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia, 2016, 30, 1979-1986.	3.3	73
115	The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1729-1732.	2.0	12
116	Optimal dosing of high-dose melphalan prior to autologous hematopoietic stem cell transplantation in a patient with AL amyloidosis and a solitary kidney. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 86-88.	0.6	1
117	Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 4523-4523.	0.6	1
118	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 645-645.	0.6	46
119	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood, 2015, 126, 2345-2347.	0.6	109
120	Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis. Bone Marrow Transplantation, 2015, 50, 868-869.	1.3	0
121	Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 229-235.	1.4	19
122	Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 156-162.	1.4	2
123	Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1445-1451.	2.0	55
124	Nonoperative Management of Spontaneous Splenic Rupture in a Patient with Light-Chain Amyloidosis: A Case Report. Journal of Vascular and Interventional Radiology, 2015, 26, 1578-1580.	0.2	2
125	The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution. Blood, 2015, 126, 5490-5490.	0.6	1
126	Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio. Blood, 2015, 126, 2956-2956.	0.6	0

#	Article	IF	Citations
127	Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients. Blood, 2015, 126, 5499-5499.	0.6	0
128	Symptoms of Depression and Anxiety Assessed By the SF-36 Questionnaire in Patients with AL Amyloidosis. Blood, 2015, 126, 3299-3299.	0.6	2
129	A Retrospective Review of Engraftment Data for Tbo-Filgrastim Vs. Filgrastim in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation. Blood, 2015, 126, 5484-5484.	0.6	0
130	Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis. Bone Marrow Transplantation, 2014, 49, 1345-1346.	1.3	6
131	Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 149-153.	1.4	11
132	Lymphadenopathy as a manifestation of amyloidosis: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 256-260.	1.4	24
133	Simultaneous presentation of kappa-restricted chronic lymphocytic leukemia and lambda light chain AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 124-127.	1.4	6
134	Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplantation, 2014, 49, 434-439.	1.3	41
135	High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Hematology/Oncology Clinics of North America, 2014, 28, 1131-1144.	0.9	16
136	Update on treatment of light chain amyloidosis. Haematologica, 2014, 99, 209-221.	1.7	93
137	Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis. American Journal of Hematology, 2014, 89, 706-708.	2.0	4
138	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood, 2014, 124, 2498-2506.	0.6	62
139	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood, 2014, 124, 3450-3450.	0.6	21
140	Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 3480-3480.	0.6	5
141	A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2014, 124, 4741-4741.	0.6	15
142	A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease. Blood, 2014, 124, 4767-4767.	0.6	2
143	Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study. Blood, 2014, 124, 3463-3463.	0.6	0
144	Clinical Presentation and Treatment Responses in IgM AL Amyloidosis, a Series of 106 Patients. Blood, 2014, 124, 4750-4750.	0.6	0

#	Article	IF	Citations
145	A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 127-130.	1.4	6
146	Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. American Journal of Hematology, 2013, 88, 719-719.	2.0	5
147	Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Bone Marrow Transplantation, 2013, 48, 1537-1542.	1.3	20
148	New Hematologic Response Criteria Predict Survival in Patients With Immunoglobulin Light Chain Amyloidosis Treated With High-Dose Melphalan and Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 2749-2750.	0.8	26
149	Microbiologically documented infections in patients undergoing highâ€dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transplant Infectious Disease, 2013, 15, 187-194.	0.7	4
150	Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica, 2013, 98, 141-146.	1.7	155
151	Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica, 2013, 98, 789-792.	1.7	50
152	Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center. Blood, 2013, 122, 3328-3328.	0.6	1
153	Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis.. Journal of Clinical Oncology, 2013, 31, 8545-8545.	0.8	0
154	Proteasome Inhibitor Based Protocol For Antibody Mediated Rejection In Kidney Transplantation. Blood, 2013, 122, 4728-4728.	0.6	0
155	Clinical Presentation and Treatment Responses In IgM-Related AL Amyloidosis. Blood, 2013, 122, 1991-1991.	0.6	1
156	Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 156-160.	1.4	10
157	Amyloidomics comes of age. Blood, 2012, 119, 1795-1796.	0.6	4
158	High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood, 2012, 120, 4445-4446.	0.6	38
159	Amyloid Deposits in the Bone Marrow of Patients with Immunoglobulin Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment. Biology of Blood and Marrow Transplantation, 2012, 18, 1935-1938.	2.0	13
160	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 2012, 26, 2317-2325.	3.3	332
161	Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation. Blood, 2012, 120, 2019-2019.	0.6	4
162	Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide. Blood, 2012, 120, 1873-1873.	0.6	0

#	Article	IF	Citations
163	Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial. Blood, 2012, 120, 4084-4084.	0.6	0
164	Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. American Journal of Blood Research, 2012, 2, 9-17.	0.6	6
165	AL amyloidosis: who, what, when, why, and where. Oncology, 2012, 26, 164, 166, 169.	0.4	0
166	Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 130-131.	1.4	27
167	Macroglossia â€“ not always AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 83-86.	1.4	19
168	Myocardial infarction with â€œclean coronariesâ€•caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 160-164.	1.4	42
169	Amyloidotic Cardiomyopathy: Multidisciplinary Approach to Diagnosis and Treatment. Heart Failure Clinics, 2011, 7, 385-393.	1.0	17
170	Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 2011, 118, 4346-4352.	0.6	259
171	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 2011, 118, 865-873.	0.6	161
172	Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica, 2011, 96, 1890-1892.	1.7	34
173	Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation. Bone Marrow Transplantation, 2011, 46, 161-162.	1.3	12
174	Cardiac Amyloidosis: Evolving Approach to Diagnosis and Management. Current Treatment Options in Cardiovascular Medicine, 2011, 13, 528-542.	0.4	20
175	Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrology Dialysis Transplantation, 2011, 26, 881-886.	0.4	99
176	Localized amyloidosis of the breast: a case series. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 72-75.	1.4	47
177	High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 127-129.	1.4	6
178	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 957-970.	0.2	40
179	A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplantation, 2011, 46, 976-980.	1.3	14
180	High-Dose Melphalan and Stem Cell Transplantation for Patients with AL Amyloidosis and Cardiac Involvement. Blood, 2011, 118, 2043-2043.	0.6	0

#	Article	IF	Citations
181	Infectious Complications In Patients with AL (Immunoglobulin Light Chain) Amyloidosis Undergoing Treatment with High-Dose Melphalan and Autologous Stem-Cell Transplantation (HDM/SCT). Blood, 2011, 118, 2041-2041.	0.6	1
182	Melphalan, Lenalidomide and Dexamethasone Combination Therapy In Patients with AL Amyloidosis. Blood, 2011, 118, 2924-2924.	0.6	0
183	Modified High-Dose Melphalan and Autologous Stem Cell Transplantation (mHDM/SCT) In the Treatment of AL Amyloidosis (AL) and/or High-Risk Myeloma (hM): Analysis of SWOG Trial S0115. Blood, 2011, 118, 2004-2004.	0.6	1
184	Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure. Transplantation, 2010, 90, 905-911.	0.5	103
185	Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood, 2010, 116, 1990-1991.	0.6	33
186	Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood, 2010, 116, 5071-5072.	0.6	59
187	Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology, 2010, 89, 579-584.	0.8	14
188	Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a â€˜melphalan recallâ€™ reaction. Bone Marrow Transplantation, 2010, 45, 21-24.	1.3	2
189	Oral Cyclic Melphalan and Dexamethasone for Patients With AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 469-472.	0.2	18
190	REDUCTION IN VENTRICULAR WALL THICKNESS FOLLOWING HIGH-DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANTATION FOR AL CARDIAC AMYLOIDOSIS. Journal of the American College of Cardiology, 2010, 55, A36.E351.	1.2	2
191	Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis. Blood, 2010, 116, 3021-3021.	0.6	3
192	High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis. Blood, 2010, 116, 3553-3553.	0.6	1
193	Macroglossia â€“ Not Always AL Amyloidosis. Blood, 2010, 116, 5007-5007.	0.6	1
194	Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis.. Journal of Clinical Oncology, 2010, 28, 8024-8024.	0.8	13
195	Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394.	0.6	1
196	Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis. Blood, 2010, 116, 3022-3022.	0.6	0
197	Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica, 2009, 94, 1029-1032.	1.7	25
198	Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 103-107.	1.4	16

#	Article	IF	Citations
199	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 2009, 114, 1489-1497.	0.6	153
200	Bortezomib and High Dose Melphalan Followed by Autologous Stem Cell Transplantation (BortHDM/SCT) for the Treatment of AL Amyloidosis: Results of a Feasibility Study.. Blood, 2009, 114, 4353-4353.	0.6	1
201	Localized AL Amyloidosis of the Breast: A Case Series.. Blood, 2009, 114, 4906-4906.	0.6	0
202	Second Autologous Peripheral Blood Stem Cell Transplantation with High Dose Melphalan (HDM/SCT) in Patients Relapsing After An Initial Course of HDM/SCT for the Treatment of AL Amyloidosis.. Blood, 2009, 114, 2318-2318.	0.6	0
203	Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis.. Blood, 2009, 114, 4352-4352.	0.6	0
204	Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.. Blood, 2009, 114, 1883-1883.	0.6	0
205	Long Term Results of High-Dose Melphalan and Autologous Stem Cell Transplantation in Non-Amyloid Monoclonal Immunoglobulin Deposition Disorders.. Blood, 2009, 114, 4356-4356.	0.6	0
206	Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leukemia and Lymphoma, 2008, 49, 1108-1115.	0.6	28
207	AL (Immunoglobulin Light-Chain) Amyloidosis. , 2008, , 551-569.		1
208	A Case of Atypical Light Chain Deposition Diseaseâ€"Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 858-867.	2.2	18
209	Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood, 2007, 109, 492-496.	0.6	262
210	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood, 2007, 110, 3561-3563.	0.6	154
211	An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 261-269.	1.4	29
212	Association of acquired von Willebrand syndrome with AL amyloidosis. American Journal of Hematology, 2007, 82, 363-367.	2.0	39
213	Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplantation, 2007, 40, 557-562.	1.3	33
214	Durable Responses to Lenalidomide (RevlimidÂ®) in Patients with AL Amyloidosis: Follow Up of a Phase II Trial.. Blood, 2007, 110, 192-192.	0.6	2
215	Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). Journal of Clinical Oncology, 2007, 25, 8050-8050.	0.8	8
216	Hepatic Response after High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Associated Liver Disease.. Blood, 2007, 110, 2873-2873.	0.6	0

#	Article	IF	Citations
217	Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood, 2006, 108, 3945-3947.	0.6	33
218	Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 339-343.	1.3	62
219	AL amyloidosis associated with B-cell lymphoproliferative disorders: Frequency and treatment outcomes. American Journal of Hematology, 2006, 81, 692-695.	2.0	47
220	Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1331-1341.	2.2	191
221	A phase II trial of lenalidomide for patients with AL amyloidosis. Journal of Clinical Oncology, 2006, 24, 7524-7524.	0.8	1
222	Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation: Final Analysis of a Prospective Trial.. Blood, 2006, 108, 612-612.	0.6	0
223	Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).. Blood, 2006, 108, 3094-3094.	0.6	10
224	Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 2005, 35, 567-575.	1.3	33
225	Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 2005, 36, 597-600.	1.3	92
226	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	2.0	1,179
227	Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 210-215.	1.4	44
228	Diaphragm paralysis in primary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 193-196.	1.4	9
229	Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.. Blood, 2005, 106, 4078-4078.	0.6	0
230	High-Dose Melphalan and Autologous Stem Cell Transplantation in Unusual Non-Amyloid Light Chain Deposition Disorders.. Blood, 2005, 106, 5476-5476.	0.6	0
231	Early Serum Free Light Chain Responses Following High-Dose Melphalan and Stem Cell Transplantation for AL Amyloidosis Predict Treatment Outcomes.. Blood, 2005, 106, 1160-1160.	0.6	0
232	High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 2004, 33, 381-388.	1.3	107
233	Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood, 2004, 104, 1888-1893.	0.6	109
234	High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study. Annals of Internal Medicine, 2004, 140, 85.	2.0	539

#	Article	IF	Citations
235	Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.. Blood, 2004, 104, 5226-5226.	0.6	4
236	Treatment of AL Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation. , 2004, , 124-126.		0
237	Successful Treatment of AL Amyloidosis Patients over Age 65 with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT).. Blood, 2004, 104, 923-923.	0.6	7
238	Serum Free Light Chain Responses after High-Dose Intravenous Melphalan and Autologous Stem Cell Transplantation for AL (Primary) Amyloidosis.. Blood, 2004, 104, 942-942.	0.6	82
239	Quantitative Serum Free Light-Chain Assay in the Diagnostic Evaluation of Al Amyloidosis. , 2004, , 90-92.		0
240	Pulsed Low Dose Intravenous Melphalan in Patients with AL Amyloidosis, Ineligible for Aggressive Treatment with High-Dose Melphalan and Stem Cell Transplantation.. Blood, 2004, 104, 2393-2393.	0.6	0
241	Treatment of Al Amyloidosis with Tandem Cycles of High Dose Melphalan and Autologous Stem Cell Transplantation. , 2004, , 124-126.		1
242	Spontaneous rupture of the spleen in AL amyloidosis. American Journal of Hematology, 2003, 74, 131-135.	2.0	56
243	High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney International, 2003, 63, 1051-1057.	2.6	59
244	Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney International, 2003, 63, 1868-1873.	2.6	63
245	Tolerability and Efficacy of Thalidomide for the Treatment of Patients with Light Chainâ€“Associated (AL) Amyloidosis. Clinical Lymphoma and Myeloma, 2003, 3, 241-246.	2.1	137
246	Persistent Pleural Effusions in Primary Systemic Amyloidosis. Chest, 2003, 124, 969-977.	0.4	106
247	Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British Journal of Haematology, 2002, 117, 886-889.	1.2	46
248	Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood, 2001, 97, 1885-1887.	0.6	200
249	An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplantation, 2001, 28, 637-642.	1.3	149
250	Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation, 2001, 28, 1105-1109.	1.3	17
251	Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL Amyloidosisâ€“Associated Renal Disease. Annals of Internal Medicine, 2001, 134, 746.	2.0	111
252	Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal of Haematology, 1999, 104, 553-559.	1.2	68

#	Article	IF	Citations
253	Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood, 1998, 91, 3662-3670.	0.6	323